Clinical Trials Logo

Obesity; Drug clinical trials

View clinical trials related to Obesity; Drug.

Filter by:
  • None
  • Page 1

NCT ID: NCT05176626 Recruiting - Obesity Clinical Trials

Long-term Effectiveness of the Antiobesity Medication Phentermine

LEAP
Start date: June 30, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.

NCT ID: NCT05162001 Enrolling by invitation - Obesity; Drug Clinical Trials

Body Weight Response With Disulfiram in Humans

Start date: November 21, 2021
Phase: Early Phase 1
Study type: Interventional

Overweight and obesity due to food that exceeds the requirements is an increasingly common global problem. Lifestyle intervention and anorectic drugs result in minimal weight loss, which tends to be easily regained. In addition, drugs tend to have too many side effects and have had to be withdrawn from management schemes and even from the market. Disulfiram (Antabuse®️) is approved by the Food and Drug Administration against chronic alcohol addiction. In a mouse study, disulfiram prevented body weight gain and negated the adverse impact of an obesogenic diet on insulin; used properly it is a safe drug. Carrying out a testing-concept study with disulfiram will allow the establishment of guidelines on clinical studies focused on its use as an adjunct in the reduction and control of body weight.

NCT ID: NCT05087342 Recruiting - Obesity Clinical Trials

Latino Semaglutide Study

LSS
Start date: December 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

NCT ID: NCT04730375 Completed - Obesity; Drug Clinical Trials

Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients

Start date: January 30, 2021
Phase: Phase 2
Study type: Interventional

• The objective of this study is to evaluate the effect of different doses of dexmedetomidine infusion intraoperative on lung mechanics and oxygenation regarding PaO2/Fraction of inspired oxygen), Intraoperative oxygenation, lung compliance (static and dynamic), dead space, and PaCO2,heart rate, mean arterial blood pressure in obese patients undergoing laparoscopic cancer surgeries

NCT ID: NCT03593668 Recruiting - Obesity; Drug Clinical Trials

Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control

Start date: December 30, 2017
Phase: Phase 4
Study type: Interventional

This is a randomized, open, controlled and single-site clinical trail to investigate the effect and safety of Benaglutide or Metformin in patients with simple obesity who have inadequate weight control.

NCT ID: NCT03141476 Completed - Obesity; Drug Clinical Trials

Adequacy of Perioperative Cefuroxime Dosage According to the BMI

Start date: March 1, 2017
Phase: Phase 4
Study type: Interventional

This study evaluates the dosage of perioperative cefuroxime for obese patients. Dosage was increased if the BMI was over 30kg/m*m and as well over 50kg/m*m. Drug levels were measured in blood and tissue.